ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) co-targeting BCMA and CD38 designed to improve cytotoxicity against multiple myeloma. Targeting of two tumor-associated an...
Үндсэн зохиолчид: | Carretero-Iglesia, L, Hall, OJ, Berret, J, Pais, D, Estoppey, C, Chimen, M, Monney, T, Loyau, J, Dreyfus, C, Macoin, J, Perez, C, Menon, V, Gruber, I, Laurendon, A, Caro, LN, Gudi, GS, Matsuura, T, van der Graaf, PH, Blein, S, Mbow, ML, Croasdale-Wood, R, Srivastava, A, Dyson, MR, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Nature Research
2024
|
Ижил төстэй зүйлс
-
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
-н: Pouleau, B, зэрэг
Хэвлэсэн: (2023) -
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
-н: Grandclément, C, зэрэг
Хэвлэсэн: (2024) -
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
-н: C. Grandclément, зэрэг
Хэвлэсэн: (2024-03-01) -
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
-н: Jeremy Loyau, зэрэг
Хэвлэсэн: (2025-12-01) -
P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
-н: C. Grandclement, зэрэг
Хэвлэсэн: (2022-06-01)